Legend Biotech Corp LEGN.OQ LEGN.O is expected to show a rise in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Somerset New Jersey-based company is expected to report a 49.8% increase in revenue to $143.868 million from $96.01 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
LSEG's mean analyst estimate for Legend Biotech Corp is for a loss of 42 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Legend Biotech Corp is 86.00, above its last closing price of $40.95.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.41 | -0.38 | -0.10 | Beat | 73.8 |
Mar. 31 2024 | -0.35 | -0.34 | -0.32 | Beat | 7.1 |
Dec. 31 2023 | -0.94 | -0.83 | -0.80 | Beat | 3.6 |
Sep. 30 2023 | -0.48 | -0.68 | -0.34 | Beat | 49.8 |
Jun. 30 2023 | -0.59 | -0.60 | -1.14 | Missed | -90 |
Mar. 31 2023 | -0.83 | -0.78 | -0.68 | Beat | 12.8 |
Dec. 31 2022 | -0.44 | ||||
Sep. 30 2022 | -0.40 |
This summary was machine generated November 8 at 16:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。